scholarly journals POS0014 TIME-TRENDS IN COCAINE AND HALLUCINOGEN USE DISORDER HOSPITALIZATIONS IN RHEUMATIC DISEASES: A NATIONAL TIME-TRENDS STUDY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 208.3-209
Author(s):  
J. Singh
Keyword(s):  
Drug Use ◽  
Time Trends ◽  
Stock Options ◽  
Musculoskeletal Diseases ◽  
Clinical Care ◽  
Epidemiological Studies ◽  
Relative Increase ◽  
Primary Position ◽  
Cocaine Use ◽  
The U.S

Background:Cocaine use disorder is a frequent cause of drug use disorders in the U.S. Although hallucinogen use disorder is less common, both are potentially preventable public health issues. To our knowledge, epidemiological studies estimating burden of cocaine or hallucinogen use disorders in common Musculoskeletal diseases (MSDs) are lacking.Objectives:To assess national time-trends in cocaine use and hallucinogen use disorders in people with MSDsMethods:This study used the U.S. National Inpatient Sample (NIS), a de-identified national all-payer inpatient health care database (https://www.hcup-us.ahrq.gov/nisoverview.jsp) from 1998-2014. The NIS is a 20% stratified sample of hospital discharges in the U.S. It is commonly used to derive national estimates of hospitalization and outcomes. Cocaine or hallucinogen use disorder hospitalization was defined in a validated approach as the presence of the following International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes: cocaine use disorder, 304.2x, or 305.6x; and hallucinogen use disorder, 304.5x or 305.3x; hospitalizations for drug use in remission, drug counseling, rehabilitation or detoxification were excluded, as in previous studies. MSDs were identified based on the respective ICD-9 codes, a validated approach (5-9), in non-primary position: Gout: 274.xx; rheumatoid arthritis (RA): 714.xx; Fibromyalgia: 729.1; osteoarthritis (OA): 715.xx; or low back pain (LBP): 724.Results:In 1998-2000, the highest frequency of cocaine use hospitalizations was in people with LBP: LBP (n=5,914), followed by OA (n=4,931), gout (n=2,093), RA (n=2,026), and fibromyalgia (n=1,620). In 2013-2014, the order changed slightly with OA (n=22,185), followed by LBP (n=16,810), gout (n=10,570), RA (n=8,975), and fibromyalgia (n=5,680). Respective rates per 1 million U.S. NIS hospitalizations in 2013-2014 and the relative increase from 1998-2000 to 2013-2014 were: Gout, 10.2 (increase, 4.1-fold); OA, 21.4 (3.5-fold); fibromyalgia, 5.48 (2.5-fold); RA, 8.66 (3.4-fold); and LBP, 16.22 (1.8-fold; Figure 1).In 1998-2000, hallucinogen use disorder hospitalizations were as follows: LBP (n=176), followed by OA (n=63), RA (n=42), fibromyalgia (n=41) and gout (n<10; cells with frequency of 10 of fewer are reported as <10 per NIS guidance). In 2013-2014, the frequency order was the similar, with the highest numbers for LBP (n=525) followed by OA (n=400), RA (n=395), gout (n=135) and fibromyalgia (n=125). Respective rates per 1 million US NIS hospitalizations in 2013-2014 and the relative increase from 1998-2000 to 2013-2014 were: Gout, 0.13 (increase, 25-fold); OA, 0.39 (5.5-fold); fibromyalgia, 0.12 (2-fold); RA, 0.38 (8.5-fold); and LBP, 0.51 (2-fold; Figure 1).Conclusion:This study confirmed an increasing rate of both, cocaine use and hallucinogen use disorder hospitalizations in people with 5 MSDs over a 17-year period from 1998-2014 in the U.S.Figure 1.Time-trends in the rates of hospitalization with cocaine use and hallucinogen use disorder (A), non-home discharge (B), and in-hospital mortality (C) per 100,000 NIS hospitalization claims. The x-axis shows rate per 100,000 NIS hospitalization claims and the y-axis the study periodsAcknowledgements:I thank John D. Cleveland, MS of the University of Alabama at Birmingham for performing data analyses according to the protocol.Disclosure of Interests:Jasvinder Singh Shareholder of: JAS owns stock options in TPT Global Tech, Vaxart pharmaceuticals and Charlotte’s Web Holdings, Inc. JAS previously owned stock options in Amarin, Viking and Moderna pharmaceuticals., Consultant of: JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio Health, Medscape, WebMD, Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, Practice Point communications, the National Institutes of Health and the American College of Rheumatology. JAS is on the speaker’s bureau of Simply Speaking. JAS is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organization that develops outcome measures in rheumatology and receives arms-length funding from 12 companies.

scholarly journals POS0510 EPIDEMIOLOGY OF COCAINE AND HALLUCINOGEN USE DISORDER HOSPITALIZATIONS IN RHEUMATIC DISEASES

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 488.1-488
Author(s):  
J. Singh
Keyword(s):  
Drug Use ◽  
Time Trends ◽  
Musculoskeletal Diseases ◽  
Clinical Care ◽  
International Classification Of Diseases ◽  
Epidemiological Studies ◽  
Relative Increase ◽  
Primary Position ◽  
Cocaine Use ◽  
The U.S

Background:Cocaine use disorder is a frequent cause of drug use disorders in the U.S. Although hallucinogen use disorder is less common, both are potentially preventable public health issues. To our knowledge, epidemiological studies estimating burden of cocaine or hallucinogen use disorders in common Musculoskeletal diseases (MSDs) are lacking.Objectives:To assess national time-trends in cocaine use and hallucinogen use disorders in people with MSDsMethods:This study used the U.S. National Inpatient Sample (NIS), a de-identified national all-payer inpatient health care database (https://www.hcup-us.ahrq.gov/nisoverview.jsp) from 1998-2014. The NIS is a 20% stratified sample of hospital discharges in the U.S. It is commonly used to derive national estimates of hospitalization and outcomes. Cocaine or hallucinogen use disorder hospitalization was defined in a validated approach as the presence of the following International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic codes: cocaine use disorder, 304.2x, or 305.6x; and hallucinogen use disorder, 304.5x or 305.3x; hospitalizations for drug use in remission, drug counseling, rehabilitation or detoxification were excluded, as in previous studies. MSDs were identified based on the respective ICD-9 codes, a validated approach (5-9), in non-primary position: Gout: 274.xx; rheumatoid arthritis (RA): 714.xx; Fibromyalgia: 729.1; osteoarthritis (OA): 715.xx; or low back pain (LBP): 724.Results:In 1998-2000, the highest frequency of cocaine use hospitalizations was in people with LBP: LBP (n=5,914), followed by OA (n=4,931), gout (n=2,093), RA (n=2,026), and fibromyalgia (n=1,620). In 2013-2014, the order changed slightly with OA (n=22,185), followed by LBP (n=16,810), gout (n=10,570), RA (n=8,975), and fibromyalgia (n=5,680). Respective rates per 1 million U.S. NIS hospitalizations in 2013-2014 and the relative increase from 1998-2000 to 2013-2014 were: Gout, 10.2 (increase, 4.1-fold); OA, 21.4 (3.5-fold); fibromyalgia, 5.48 (2.5-fold); RA, 8.66 (3.4-fold); and LBP, 16.22 (1.8-fold; figure 1).Figure 1.Time-trends in the rates of hospitalization with cocaine use and hallucinogen use disorder (A), non-home discharge (B), and in-hospital mortality (C) per 100,000 NIS hospitalization claims. The x-axis shows rate per 100,000 NIS hospitalization claims and the y-axis the study periodsIn 1998-2000, hallucinogen use disorder hospitalizations were as follows: LBP (n=176), followed by OA (n=63), RA (n=42), fibromyalgia (n=41) and gout (n<10; cells with frequency of 10 of fewer are reported as <10 per NIS guidance). In 2013-2014, the frequency order was the similar, with the highest numbers for LBP (n=525) followed by OA (n=400), RA (n=395), gout (n=135) and fibromyalgia (n=125). Respective rates per 1 million US NIS hospitalizations in 2013-2014 and the relative increase from 1998-2000 to 2013-2014 were: Gout, 0.13 (increase, 25-fold); OA, 0.39 (5.5-fold); fibromyalgia, 0.12 (2-fold); RA, 0.38 (8.5-fold); and LBP, 0.51 (2-fold; figure 1).Conclusion:This study confirmed an increasing rate of both, cocaine use and hallucinogen use disorder hospitalizations in people with 5 MSDs over a 17-year period from 1998-2014 in the U.S.Acknowledgements:John D. Cleveland, MS of the University of Alabama at Birmingham for performing data analyses according to the protocol.Disclosure of Interests:Jasvinder Singh Speakers bureau: JAS is on the speaker’s bureau of Simply Speaking. JAS is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organization that develops outcome measures in rheumatology and receives arms-length funding from 12 companies., Consultant of: consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio Health, Medscape, WebMD, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Practice Point communications, the National Institutes of Health and the American College of Rheumatology.

Novel Drugs and Biologics of 2016: A Boom for Neurodrugs in the Pipelin

2017 ◽  
Vol 10 (5) ◽  
pp. 3809-3814
Author(s):  
D Samba Reddy
Keyword(s):  
Muscular Atrophy ◽  
Clinical Care ◽  
New Drugs ◽  
Essential Medicines ◽  
High Demand ◽  
The Past ◽  
Novel Drugs ◽  
Innovative Products ◽  
Cns Drugs ◽  
The U.S

This article provides a brief overview of novel drugs approved by the U.S. FDA in 2016.  It also focuses on the emerging boom in the development of neurodrugs for central nervous system (CNS) disorders. These new drugs are innovative products that often help advance clinical care worldwide, and in 2016, twenty-two such drugs were approved by the FDA. The list includes the first new drug for disorders such as spinal muscular atrophy, Duchenne muscular dystrophy or hallucinations and delusions of Parkinson’s disease, among several others. Notably, nine of twenty-two (40%) were novel CNS drugs, indicating the industry shifting to neurodrugs. Neurodrugs are the top selling pharmaceuticals worldwide, especially in America and Europe. Therapeutic neurodrugs have proven their significance many times in the past few decades, and the CNS drug portfolio represents some of the most valuable agents in the current pipeline. Many neuroproducts are vital or essential medicines in the current therapeutic armamentarium, including dozens of “blockbuster drugs” (drugs with $1 billion sales potential).  These drugs include antidepressants, antimigraine medications, and anti-epilepsy medications. The rise in neurodrugs’ sales is predominantly due to increased diagnoses of CNS conditions. The boom for neuromedicines is evident from the recent rise in investment, production, and introduction of new CNS drugs.  There are many promising neurodrugs still in the pipeline, which are developed based on the validated “mechanism-based” strategy. Overall, disease-modifying neurodrugs that can prevent or cure serious diseases, such as multiple sclerosis, epilepsy, and Alzheimer’s disease, are in high demand. 

Substance Use Portrayal in Oscar-nominated Movies

2020 ◽  
Vol 12 ◽  
Author(s):  
João Mauricio Castaldelli-Maia ◽  
Felipe Gil ◽  
Antonio Ventriglio ◽  
Julio Torales ◽  
Ligia Florio ◽  
...  
Keyword(s):  
Substance Use ◽  
Drug Use ◽  
Epidemiological Studies ◽  
Progressive Increase ◽  
Media Content ◽  
Media Content Analysis ◽  
Monitoring Drug ◽  
And Gender ◽  
Multiple Drugs ◽  
Gender Convergence

Background: As one of the forms of media and art most consumed in the world, Oscar-nominated movies should have their drug use representation monitored because of possibly influencing but also reflecting society’s behavior. Objective: To investigate drug use representation in scenes from movies nominated for the Academy Awards (Oscar) from 2008-2011, through media content analysis. Methods: 437 scenes from Oscar-nominated movies (best film, best actor and best actress categories) showing drug consumption and/or its effects were assessed. Each drug represented and identified in a given scene (i.e., drug use incident) was counted as a unit for the present study (n = 515). Survey settings were used to control for over- or under-estimation of the prevalence of a variable in a given year or movie. Results: All the Oscar-nominated movies portrayed at least one scene of drug use. There was a massive predominance of alcohol and tobacco in movies, with a high use among men who also use drugs, habitually or occasionally, but related to stress/tension, predominantly at home. However, there was a significant progressive increase in the use of drugs other than alcohol and tobacco, multiple drugs, and by women. Conclusion: These findings echo epidemiological studies on substance use in western countries, an overall trend towards greater home drug use representation and gender convergence since 1970, which increased since 2000. Monitoring drug use representation in Oscar-nominated movies may represent an important public health tool.

scholarly journals Evaluation of a Cryptococcal Antigen Lateral Flow Assay and Cryptococcal Antigen Positivity at a Large Public Hospital in Atlanta, Georgia

2021 ◽  
Author(s):  
Kristin R V Harrington ◽  
Yun F (Wayne) Wang ◽  
Paulina A Rebolledo ◽  
Zhiyong Liu ◽  
Qianting Yang ◽  
...  
Keyword(s):  
Public Hospital ◽  
Clinical Care ◽  
Latex Agglutination ◽  
Lateral Flow ◽  
Lateral Flow Assay ◽  
Clinical Implications ◽  
Cryptococcal Antigen ◽  
Cryptococcal Disease ◽  
Percent Positivity ◽  
The U.S

Abstract Background Cryptococcus neoformans is a major cause of morbidity and mortality among HIV-infected persons worldwide, and there is scarce recent data on cryptococcal antigen (CrAg) positivity in the U.S. We sought to determine the frequency of cryptococcal disease and compare the performance of a CrAg lateral flow assay (LFA) versus latex agglutination (LA) test. Methods All patients from Grady Health System in Atlanta who had a serum or cerebrospinal fluid (CSF) sample sent for CrAg testing as part of clinical care from November 2017 – July 2018 were included. Percent positivity and test agreement were calculated. Results Among 467 patients, 557 diagnostic tests were performed; 413 on serum and 144 on CSF. Mean age was 44 years, most were male (69%) and had HIV (79%). Twenty-four (6.4%, CI95% = 4.1, 9.4) patients were serum CrAg positive, and eight (5.8%, CI95% = 2.6, 11.2) individuals tested positive for CSF CrAg. While overall agreement between the LA and LFA was substantial to high for CSF (κ= 0.71, CI95% = 0.51, 0.91) and serum (κ= 0.93, CI95% = 0.86, 1.00), respectively, there were important discrepancies. Five patients had false-positive CSF LA tests which affected clinical care, and four patients had discordant serum tests. Conclusions We found a moderately high proportion of cryptococcal disease and important discrepancies between the LA test and LFA. Clinical implications of these findings include accurate detection of serum CrAg and averting unnecessary treatment of meningitis with costly medications associated with high rates of adverse events.

Labor Market Effects of Marijuana and Cocaine Use among Young Men

ILR Review ◽  
1992 ◽  
Vol 45 (3) ◽  
pp. 435-448 ◽  
Author(s):  
Charles A. Register ◽  
Donald R. Williams
Keyword(s):  
Labor Market ◽  
Drug Use ◽  
Longitudinal Survey ◽  
National Longitudinal Survey ◽  
Productivity Effect ◽  
Cocaine Use ◽  
Market Effects ◽  
Net Productivity ◽  
Using Data

Using data on marijuana and cocaine use from the 1984 National Longitudinal Survey of Youth, the authors examine the hypothesis that drug use reduces labor market productivity, as measured by wages. From an analysis that controls for the probability of employment and the endogeneity of drug use, they find that although long-term and on-the-job use of marijuana negatively affected wages, the net productivity effect for all marijuana users (both those who engaged in long-term or on-the-job use and those who did not) was positive. No statistically significant association was found between cocaine use and productivity.

Public Health Consequences of Macrolide Use in Food Animals: A Deterministic Risk Assessment†

2004 ◽  
Vol 67 (5) ◽  
pp. 980-992 ◽  
Author(s):  
H. SCOTT HURD ◽  
STEPHANIE DOORES ◽  
DERMOT HAYES ◽  
ALAN MATHEW ◽  
JOHN MAURER ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Drug Use ◽  
Treatment Failure ◽  
Deterministic Model ◽  
Veterinary Drug ◽  
Resistant Bacteria ◽  
Guidance Document ◽  
Qualitative Risk Assessment ◽  
Food Animals ◽  
The U.S

The potential impact on human health from antibiotic-resistant bacteria selected by use of antibiotics in food animals has resulted in many reports and recommended actions. The U.S. Food and Drug Administration Center for Veterinary Medicine has issued Guidance Document 152, which advises veterinary drug sponsors of one potential process for conducting a qualitative risk assessment of drug use in food animals. Using this guideline, we developed a deterministic model to assess the risk from two macrolide antibiotics, tylosin and tilmicosin. The scope of modeling included all label claim uses of both macrolides in poultry, swine, and beef cattle. The Guidance Document was followed to define the hazard, which is illness (i) caused by foodborne bacteria with a resistance determinant, (ii) attributed to a specified animal-derived meat commodity, and (iii) treated with a human use drug of the same class. Risk was defined as the probability of this hazard combined with the consequence of treatment failure due to resistant Campylobacter spp. or Enterococcus faecium. A binomial event model was applied to estimate the annual risk for the U.S. general population. Parameters were derived from industry drug use surveys, scientific literature, medical guidelines, and government documents. This unique farm-to-patient risk assessment demonstrated that use of tylosin and tilmicosin in food animals presents a very low risk of human treatment failure, with an approximate annual probability of less than 1 in 10 million Campylobacter-derived and approximately 1 in 3 billion E. faecium–derived risk.

New Estimates of the Effect of Marijuana and Cocaine Use on Wages

ILR Review ◽  
1994 ◽  
Vol 47 (3) ◽  
pp. 454-470 ◽  
Author(s):  
Robert Kaestner
Keyword(s):  
Drug Use ◽  
Illicit Drug ◽  
Unobserved Heterogeneity ◽  
Illicit Drug Use ◽  
Longitudinal Survey ◽  
National Longitudinal Survey ◽  
Cross Sectional ◽  
Cocaine Use ◽  
Wage Effects ◽  
Positive Effect

Using the 1984 and 1988 waves of the National Longitudinal Survey of Youth, this study provides an update of several previous cross-sectional estimates of the effect of illicit drug use on wages, as well as the first longitudinal estimates of that effect. The cross-sectional results, which are generally consistent with the surprising findings of previous research, suggest that illicit drug use has a large, positive effect on wages. The longitudinal estimates, which control for unobserved heterogeneity in the sample, are mixed: among men, the estimated wage effects of both marijuana and cocaine use are negative, but among women, the effect of cocaine use remains positive and large. Because the longitudinal model is imprecisely estimated, however, those results are inconclusive.

Time Trends and Geographical Variation in Parkinson's Disease in Scotland

1992 ◽  
Vol 37 (4) ◽  
pp. 112-115 ◽  
Author(s):  
W.C.S. Smith ◽  
W.J. Mutch
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Time Trends ◽  
Geographical Variation ◽  
The Elderly ◽  
Epidemiological Studies ◽  
Space Distribution ◽  
Mortality Data ◽  
Time And Space ◽  
Factors Affecting

Parkinson's disease is a common and disabling condition which principally affects the elderly. The time and space distribution of Parkinson's disease has been examined to determine if it provides clues as to aetiology and factors affecting its distribution. Previous studies have used mortality data,1 data from epidemiological studies,2 and pre scribing information particularly with regard to the use of levodopa.3 These studies have looked within countries and between countries.

Cocaine, kicks, and strain: patterns of substance use in Milwaukee gangs

1998 ◽  
Vol 25 (1) ◽  
pp. 113-145 ◽  
Author(s):  
John M. Hagedorn ◽  
Jose Torres ◽  
Greg Giglio
Keyword(s):  
Substance Use ◽  
Drug Use ◽  
Peer Group ◽  
Social Control Theory ◽  
Gang Members ◽  
Cocaine Use ◽  
Differential Association Theory ◽  
History Of ◽  
Family Variables ◽  
Female Gang Members

This study describes the patterns of substance use by male and female gang members in Milwaukee, Wisconsin, from their teenage years in the 1980s into adulthood. Milwaukee gangs started out as one form of neighborhood-based drug-using peer group. There was much variation in drug use, and family variables explained little of the variation. Male gang members raised in families with a history of gang involvement and drug use were more likely than other gang members to use cocaine and to use it seriously. On the other hand, severe family distress was not related to onset, duration, or seriousness of cocaine use in either males or females. Cocaine use for both males and females increased in adulthood. It appears that the etiology of adult and adolescent drug use may differ. Neither social control theory nor differential association theory is well suited to explain the variations in gang drug use by age or gender.

Sign in / Sign up

Export Citation Format

Share Document